Developer docs
API playgroundTry for free, no card

Search company profiles

AWAK Technologies

Full company profile

uuid0000mpc

Namestring
AWAK Technologies
Legal namestring
AWAK Technologies
Websiteurl
awak.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

AWAK Technologies is a Singapore-based medical device company founded in 2007 that develops wearable and portable peritoneal dialysis systems intended for at-home treatment of chronic kidney disease (CKD). The company's core product is a miniaturized wearable peritoneal dialysis platform built around proprietary regenerative dialysis sorbent technology, designed to replicate the function of a normal kidney and free patients from the immobility and clinic-based scheduling imposed by conventional hemodialysis machines.

The platform is targeted at two complementary customer groups: chronic kidney disease patients who require regular dialysis and want treatment delivered outside clinical settings, and home healthcare providers building out home-based renal care programs. AWAK is currently pre-commercial; it has no paying customers, no disclosed pricing, and generates no revenue. The company is advancing through a structured regulatory pathway, running a pre-pivotal trial in Singapore and preparing a pivotal trial in the United States to support future FDA clearance and North American market entry.

AWAK's go-to-market model is sales-led and hardware-based: once regulatory approvals are secured, the company plans to distribute its wearable dialysis devices directly to healthcare providers and patients in Singapore and the United States. Capital to fund this clinical and product roadmap has come from venture investors, including a Series B of over US$20 million in September 2023 (one of the largest MedTech raises in Southeast Asia that year) led by Lion X Ventures and Vickers Venture Partners, following a roughly US$40 million round in 2019 led by Vickers Venture Partners with participation from Enterprise Singapore and Seeds Capital.

Short descriptiontext

AWAK Technologies is a Singapore-based medical device company developing a wearable peritoneal dialysis system with proprietary regenerative sorbent technology for at-home treatment of chronic kidney disease patients, currently pre-commercial and advancing through clinical trials in Singapore and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable dialysis devices, peritoneal dialysis systems, home dialysis technology, kidney failure treatment, portable medical devices
Industry3 codes
PRIMARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLAFAEAG
Home Dialysis Support & Training Providers
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Dialysis Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Wearable Dialysis Devices
TypeHardware Sales
Description

The company develops and plans to commercialize wearable peritoneal dialysis systems for at-home use by chronic kidney disease patients. Revenue will be generated through device sales once regulatory approvals are obtained.

en.prnasia.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AWAK Technologies develops a wearable peritoneal dialysis system designed for at-home treatment of chronic kidney disease patients. The device miniaturizes traditional dialysis machines into a portable, regenerative form factor, enabling continuous dialysis outside clinical settings. The product is currently in clinical development, with a pre-pivotal trial underway in Singapore and a pivotal trial planned in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Improved patient quality of life through portable, at-home dialysis treatment
Product and service1 record
1Wearable Peritoneal Dialysis System
CategoryRenal Care Medical Devices
Description

A wearable peritoneal dialysis system designed for at-home care of chronic kidney disease patients. The device enables portable dialysis treatment, miniaturizing traditional dialysis machines for increased convenience and improved quality of life. Currently undergoing pre-pivotal clinical trials in Singapore with a pivotal trial planned in the United States.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Outset Medical develops the Tablo, a portable/home hemodialysis system aimed at simplifying in-home and clinic-based dialysis. Like AWAK, it focuses on miniaturization and ease of use to enable home-based renal replacement therapy, making it the closest direct analog in the wearable/portable dialysis category.

TypeDirect peer
Description

Baxter is the global leader in peritoneal dialysis systems (HomeChoice, Amia APD) and a dominant incumbent in the PD market AWAK is targeting. It competes head-to-head with AWAK in home PD and represents both the primary competitive threat and a potential strategic acquirer.

TypeBroad incumbent
Description

Fresenius Medical Care is the world's largest dialysis products and services company, operating thousands of dialysis centers and producing a broad portfolio of dialysis machines, PD systems, and consumables. It competes with AWAK across virtually every dialysis modality and is the most formidable incumbent in the category.

TypeDirect peer
Description

Quanta develops the SC+ portable hemodialysis system for home and clinic use, with an emphasis on simplicity and portability. It is a directly comparable device-focused peer pursuing the same home-dialysis shift as AWAK.

TypeBroad incumbent
Description

DaVita is one of the largest US dialysis service providers with significant investment in home dialysis programs (including PD). While primarily a services operator rather than a device maker, it is a major customer/partner channel for home-dialysis device companies like AWAK.

TypeEmerging player
Description

Swiss medtech Debiotech has worked on miniaturized/wearable artificial kidney and dialysis concepts. It is an emerging peer in the wearable dialysis innovation space, sharing AWAK's focus on miniaturization but at an earlier commercialization stage.

TypeOthers
Description

US Renal Care is a mid-sized US dialysis services provider with growing home dialysis offerings. It is relevant as a potential channel/customer for AWAK's wearable PD system rather than a direct device competitor.

TypeEmerging player
Description

Diality is developing a portable hemodialysis platform targeting both clinic and home settings. As a smaller, venture-backed device competitor, it competes with AWAK for capital and clinical positioning in the home dialysis category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AWAK Technologies

Wearable Dialysis Medical Devicesawak.com

AWAK Technologies is a Singapore-based medical device company developing a wearable peritoneal dialysis system with proprietary regenerative sorbent technology for at-home treatment of chronic kidney disease patients, currently pre-commercial and advancing through clinical trials in Singapore and the United States.

What AWAK Technologies does

AWAK Technologies is a Singapore-based medical device company founded in 2007 that develops wearable and portable peritoneal dialysis systems intended for at-home treatment of chronic kidney disease (CKD). The company's core product is a miniaturized wearable peritoneal dialysis platform built around proprietary regenerative dialysis sorbent technology, designed to replicate the function of a normal kidney and free patients from the immobility and clinic-based scheduling imposed by conventional hemodialysis machines.

The platform is targeted at two complementary customer groups: chronic kidney disease patients who require regular dialysis and want treatment delivered outside clinical settings, and home healthcare providers building out home-based renal care programs. AWAK is currently pre-commercial; it has no paying customers, no disclosed pricing, and generates no revenue. The company is advancing through a structured regulatory pathway, running a pre-pivotal trial in Singapore and preparing a pivotal trial in the United States to support future FDA clearance and North American market entry.

AWAK's go-to-market model is sales-led and hardware-based: once regulatory approvals are secured, the company plans to distribute its wearable dialysis devices directly to healthcare providers and patients in Singapore and the United States. Capital to fund this clinical and product roadmap has come from venture investors, including a Series B of over US$20 million in September 2023 (one of the largest MedTech raises in Southeast Asia that year) led by Lion X Ventures and Vickers Venture Partners, following a roughly US$40 million round in 2019 led by Vickers Venture Partners with participation from Enterprise Singapore and Seeds Capital.

AWAK Technologies firmographics

Firmographics
Name
AWAK Technologies
Legal name
AWAK Technologies
Website
https://awak.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
AWAK Technologies is a Singapore-based medical device company developing a wearable peritoneal dialysis system with proprietary regenerative sorbent technology for at-home treatment of chronic kidney disease patients, currently pre-commercial and advancing through clinical trials in Singapore and the United States.
Ownership category
akta.pro rank

AWAK Technologies industry classification

Industry
Product category
Wearable Dialysis Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLAFAEAG
Home Dialysis Support & Training Providers
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Wearable dialysis devices
  • Peritoneal dialysis systems
  • Home dialysis technology
  • Kidney failure treatment
  • Portable medical devices

Where AWAK Technologies is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

AWAK Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Wearable Dialysis Devices: The company develops and plans to commercialize wearable peritoneal dialysis systems for at-home use by chronic kidney disease patients. Revenue will be generated through device sales once regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

AWAK Technologies product offering

Product offering

Core offering

AWAK Technologies develops a wearable peritoneal dialysis system designed for at-home treatment of chronic kidney disease patients. The device miniaturizes traditional dialysis machines into a portable, regenerative form factor, enabling continuous dialysis outside clinical settings. The product is currently in clinical development, with a pre-pivotal trial underway in Singapore and a pivotal trial planned in the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Wearable Peritoneal Dialysis System A wearable peritoneal dialysis system designed for at-home care of chronic kidney disease patients. The device enables portable dialysis treatment, miniaturizing traditional dialysis machines for increased convenience and improved quality of life. Currently undergoing pre-pivotal clinical trials in Singapore with a pivotal trial planned in the United States.

Quantifiable outcome

  • Improved patient quality of life through portable, at-home dialysis treatment

Companies that use AWAK Technologies

Customer profile

Segments2 records

Ideal customer profiles2 records

AWAK Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

AWAK Technologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

AWAK Technologies competitors and assessment

Company assessment

Direct peers

  • Outset Medical: Outset Medical develops the Tablo, a portable/home hemodialysis system aimed at simplifying in-home and clinic-based dialysis. Like AWAK, it focuses on miniaturization and ease of use to enable home-based renal replacement therapy, making it the closest direct analog in the wearable/portable dialysis category.
  • Baxter International: Baxter is the global leader in peritoneal dialysis systems (HomeChoice, Amia APD) and a dominant incumbent in the PD market AWAK is targeting. It competes head-to-head with AWAK in home PD and represents both the primary competitive threat and a potential strategic acquirer.
  • Quanta Dialysis Technologies: Quanta develops the SC+ portable hemodialysis system for home and clinic use, with an emphasis on simplicity and portability. It is a directly comparable device-focused peer pursuing the same home-dialysis shift as AWAK.

Broad incumbents

  • Fresenius Medical Care: Fresenius Medical Care is the world's largest dialysis products and services company, operating thousands of dialysis centers and producing a broad portfolio of dialysis machines, PD systems, and consumables. It competes with AWAK across virtually every dialysis modality and is the most formidable incumbent in the category.
  • DaVita: DaVita is one of the largest US dialysis service providers with significant investment in home dialysis programs (including PD). While primarily a services operator rather than a device maker, it is a major customer/partner channel for home-dialysis device companies like AWAK.

Emerging players

  • Debiotech: Swiss medtech Debiotech has worked on miniaturized/wearable artificial kidney and dialysis concepts. It is an emerging peer in the wearable dialysis innovation space, sharing AWAK's focus on miniaturization but at an earlier commercialization stage.
  • Diality: Diality is developing a portable hemodialysis platform targeting both clinic and home settings. As a smaller, venture-backed device competitor, it competes with AWAK for capital and clinical positioning in the home dialysis category.

Others

  • US Renal Care: US Renal Care is a mid-sized US dialysis services provider with growing home dialysis offerings. It is relevant as a potential channel/customer for AWAK's wearable PD system rather than a direct device competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

AWAK Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AWAK Technologies leadership team

Management profile

Number of profiles

Profiles7 records

AWAK Technologies funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AWAK Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AWAK Technologies

What does AWAK Technologies do?

AWAK Technologies develops a wearable peritoneal dialysis system designed for at-home treatment of chronic kidney disease patients. The device miniaturizes traditional dialysis machines into a portable, regenerative form factor, enabling continuous dialysis outside clinical settings. The product is currently in clinical development, with a pre-pivotal trial underway in Singapore and a pivotal trial planned in the United States.

Is AWAK Technologies a public or private company?

AWAK Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was AWAK Technologies founded?

AWAK Technologies was founded in 2007. It employs 101 to 250 people.

Where is AWAK Technologies based?

AWAK Technologies is headquartered in Singapore, Singapore, in the Asia region.

How does AWAK Technologies make money?

One revenue line is on record: wearable Dialysis Devices.

Who are AWAK Technologies's main competitors?

Direct peers on record are Outset Medical, Baxter International and Quanta Dialysis Technologies. Broad incumbents are Fresenius Medical Care and DaVita. Emerging players are Debiotech and Diality. US Renal Care is listed as an others.

Does AWAK Technologies have an API?

No public API is recorded for AWAK Technologies.

What industry is AWAK Technologies in?

AWAK Technologies's product category is Wearable Dialysis Medical Devices. Its primary akta.pro industry code is HLAHAKAB, Peritoneal Dialysis (PD) Systems & Supplies, with a secondary code of HLAFAEAG, Home Dialysis Support & Training Providers. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Grand View ResearchWearable Artificial Kidney Market To Reach $853.3Mn By 2030The global wearable artificial kidney market is projected to reach $853.3 million by 2030, growing at a 6.9% CAGR from 2025 to 2030. Growth is driven by rising chronic kidney disease cases and FDA-approved prototypes from firms like Blood Purification Technologies and AWAK Technologies.openPR.comWearable Artificial Organs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2031)The wearable artificial organs market is projected to grow at a 7.60% CAGR from 2024 to 2031, driven by chronic disease prevalence and technological advances. Key players include Medtronic, Cochlear, and AWAK Technology, with Medtronic reporting $30.6 billion in 2020 sales.Incubees$20+ M Series B funding secured by med-tech firm AWAK Technologies – IncubeesSingaporean med-tech firm AWAK Technologies announced it secured over $20 million in Series B funding led by Lion X Ventures and Vickers Venture Partners. The capital will be used to complete human pre-pivotal clinical trials with Singapore General Hospital and prepare for a pivotal trial in the United States scheduled for 2025.TNGlobalSingaporean med-tech firm AWAK Technologies raises $20+ million in Series B fundingAWAK Technologies, a Singaporean med-tech firm, raised over $20 million in Series B funding co-led by Lion X Ventures and Vickers Venture Partners. The proceeds will fund its human pre-pivotal clinical trial with Singapore General Hospital and enhancements to its ultraportable PD device for a U.S. pivotal trial expected in 2025.FinSMEsAwak Technologies Raises Over USD$20M in Series B FundingSingapore-based Awak Technologies raised over USD$20 million in Series B funding, led by Lion X Ventures and Vickers Venture Partners. The company plans to utilize the capital to complete its human pre-pivotal clinical trial and prepare for a US market launch. This investment supports the development of its ultra-portable peritoneal dialysis system designed for home use.BioSpaceAWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIALAWAK Technologies raised over US$20 million in a Series B funding round co-led by Lion X Ventures and Vickers Venture Partners to advance its wearable dialysis device for a pivotal trial in the US. This fundraising is notable as one of the largest MedTech events in Southeast Asia for 2023, allowing AWAK to enhance its products and move closer to launching in the US market.PR Newswire APACAWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIALAWAK Technologies has raised over US$20 million in a Series B funding round led by Lion X Ventures and Vickers Venture Partners to support the development of its wearable peritoneal dialysis device. The company plans to use the proceeds to complete ongoing pre-pivotal clinical trials with Singapore General Hospital and prepare for a pivotal trial in the United States expected to begin in 2025.PR NewswireAWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis deviceAWAK Technologies and Singapore General Hospital launched a pre-pivotal clinical trial for their wearable peritoneal dialysis device, enrolling the first subject. The device, granted FDA Breakthrough Device Designation, follows a first-in-human trial with no serious adverse events. The trial aims to test the enhanced device before a pivotal trial for regulatory approval.PR NewswireAWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis deviceAWAK Technologies and Singapore General Hospital launched a pre-pivotal clinical trial for their wearable peritoneal dialysis device, enrolling the first subject. The device, granted FDA Breakthrough Device Designation, follows a first-in-human trial with no serious adverse events. The trial aims to refine the device before a pivotal trial for regulatory approval.